IMAB
Price
$2.45
Change
+$0.16 (+6.99%)
Updated
Jun 6 closing price
Capitalization
186.19M
86 days until earnings call
NURPF
Price
$8.86
Change
-$0.69 (-7.23%)
Updated
Jun 6 closing price
Capitalization
1.16B
Interact to see
Advertisement

IMAB vs NURPF

Header iconIMAB vs NURPF Comparison
Open Charts IMAB vs NURPFBanner chart's image
I-MAB
Price$2.45
Change+$0.16 (+6.99%)
Volume$1.68M
Capitalization186.19M
Neuren Pharmaceuticals
Price$8.86
Change-$0.69 (-7.23%)
Volume$100
Capitalization1.16B
IMAB vs NURPF Comparison Chart
Loading...
IMAB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
IMAB vs. NURPF commentary
Jun 08, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is IMAB is a Buy and NURPF is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 08, 2025
Stock price -- (IMAB: $1.17 vs. NURPF: $8.17)
Brand notoriety: IMAB and NURPF are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: IMAB: 546% vs. NURPF: 15%
Market capitalization -- IMAB: $186.19M vs. NURPF: $1.16B
IMAB [@Biotechnology] is valued at $186.19M. NURPF’s [@Biotechnology] market capitalization is $1.16B. The market cap for tickers in the [@Biotechnology] industry ranges from $323.27B to $0. The average market capitalization across the [@Biotechnology] industry is $2.25B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

IMAB’s FA Score shows that 0 FA rating(s) are green whileNURPF’s FA Score has 0 green FA rating(s).

  • IMAB’s FA Score: 0 green, 5 red.
  • NURPF’s FA Score: 0 green, 5 red.
According to our system of comparison, IMAB is a better buy in the long-term than NURPF.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

IMAB’s TA Score shows that 5 TA indicator(s) are bullish.

  • IMAB’s TA Score: 5 bullish, 4 bearish.

Price Growth

IMAB (@Biotechnology) experienced а +24.05% price change this week, while NURPF (@Biotechnology) price change was +0.39% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.11%. For the same industry, the average monthly price growth was +10.01%, and the average quarterly price growth was -2.16%.

Reported Earning Dates

IMAB is expected to report earnings on Sep 02, 2025.

Industries' Descriptions

@Biotechnology (+4.11% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
NURPF($1.16B) has a higher market cap than IMAB($186M). IMAB YTD gains are higher at: 37.647 vs. NURPF (7.926).
IMABNURPFIMAB / NURPF
Capitalization186M1.16B16%
EBITDA-212.17MN/A-
Gain YTD37.6477.926475%
P/E RatioN/A13.60-
Revenue3.27MN/A-
Total Cash184MN/A-
Total Debt3.78MN/A-
FUNDAMENTALS RATINGS
NURPF: Fundamental Ratings
NURPF
OUTLOOK RATING
1..100
29
VALUATION
overvalued / fair valued / undervalued
1..100
69
Overvalued
PROFIT vs RISK RATING
1..100
51
SMR RATING
1..100
96
PRICE GROWTH RATING
1..100
57
P/E GROWTH RATING
1..100
85
SEASONALITY SCORE
1..100
n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
IMAB
RSI
ODDS (%)
Bearish Trend 12 days ago
83%
Stochastic
ODDS (%)
Bearish Trend 12 days ago
81%
Momentum
ODDS (%)
Bullish Trend 12 days ago
79%
MACD
ODDS (%)
N/A
TrendWeek
ODDS (%)
Bullish Trend 12 days ago
76%
TrendMonth
ODDS (%)
Bullish Trend 12 days ago
80%
Advances
ODDS (%)
Bullish Trend 12 days ago
77%
Declines
ODDS (%)
Bearish Trend 26 days ago
86%
BollingerBands
ODDS (%)
Bearish Trend 12 days ago
90%
Aroon
ODDS (%)
Bullish Trend 12 days ago
76%
View a ticker or compare two or three
Interact to see
Advertisement
IMAB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
AAPL200.420.21
+0.10%
Apple
SPY587.73-3.42
-0.58%
SPDR® S&P 500® ETF
BTC.X107802.330000-1192.312500
-1.09%
Bitcoin cryptocurrency
TSLA356.90-5.99
-1.65%
Tesla
GME31.21-3.80
-10.85%
GameStop Corp

IMAB and

Correlation & Price change

A.I.dvisor tells us that IMAB and RPRX have been poorly correlated (+31% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that IMAB and RPRX's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To IMAB
1D Price
Change %
IMAB100%
+12.50%
RPRX - IMAB
31%
Poorly correlated
-0.18%
IRD - IMAB
31%
Poorly correlated
-1.47%
TPST - IMAB
28%
Poorly correlated
+1.94%
LGND - IMAB
27%
Poorly correlated
-1.43%
UBX - IMAB
26%
Poorly correlated
-7.71%
More

NURPF and

Correlation & Price change

A.I.dvisor tells us that NURPF and ASPHF have been poorly correlated (+30% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that NURPF and ASPHF's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NURPF
1D Price
Change %
NURPF100%
N/A
ASPHF - NURPF
30%
Poorly correlated
N/A
TCRT - NURPF
24%
Poorly correlated
-6.06%
IMAB - NURPF
23%
Poorly correlated
+12.50%
CLSD - NURPF
23%
Poorly correlated
-4.04%
SRZN - NURPF
22%
Poorly correlated
+3.11%
More